1-10 of 10
William Donnellan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Wei-Han Cheng, Michael Werner, Jonathan Abbas, William Donnellan
Journal: Blood
Blood (2022) 140 (Supplement 1): 683–684.
https://doi.org/10.1182/blood-2022-157509
Published: 2022
Journal Articles

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

Sudhir Manda, Bertrand Anz, III, Christopher Benton, E. Randolph Broun, Habte Yimer, John Renshaw, George F. Geils, Jr., Jose Cruz, Suzanne Fanning, Jason Melear, Jeff P. Sharman, Kingston Kang, Anders Svensson, Madhavi Pai, William Donnellan
Journal: Blood
Blood (2021) 138 (Supplement 1): 1265.
https://doi.org/10.1182/blood-2021-144886
Published: 2021
Journal Articles

Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial

Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William Donnellan, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammad Kazemi, Ioannis Mantzaris, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich G. Steidl, Britta Will, Aditi Shastri, Amit Verma
Journal: Blood
Blood (2021) 138 (Supplement 1): 65.
https://doi.org/10.1182/blood-2021-146597
Published: 2021
Journal Articles

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Pankit Vachhani, Jonathan A. Abbas, Evelyn M. Flahavan, Esprit Ma, Tao Xu, Huan Jin, Melissa Montez, Weize Huang, Anda Gershon, Grace Ku, Brannon Flores, Maika Onishi, Cat N. Bui, William Donnellan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2290.
https://doi.org/10.1182/blood-2021-147851
Published: 2021
Journal Articles

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Ahmed Aribi, MD, Anjali S Advani, MD, William Donnellan, MD, Amir T. Fathi, MD, Marcello Rotta, MD, Benjamin K. Tomlinson, MD, Pankit Vachani, MD, Jay Yang, MD, Phoenix Ho, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-136203
Published: 2020
Journal Articles

Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

William Donnellan, MD, Tao Xu, Esprit Ma, Huan Jin, Melissa Montez, Michelle Choi, Grace Ku, Raj Anand Rajeswaran, Giridharan Ramsingh, Evelyn M. Flahavan
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-134820
Published: 2020
Journal Articles

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Stephen Couban, MDBSc, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, MD PhD, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Ian Templeton, Francesco Passamonti
Journal: Blood
Blood (2017) 130 (Supplement 1): 4179.
https://doi.org/10.1182/blood.V130.Suppl_1.4179.4179
Published: 2017
Journal Articles

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Wolfram Brugger, MDPhD, Susan Ashton, Carrie A. Adelman, Nicolas Floc'h, Paula Taylor, Maureen Hattersley, PhD, Shenghua Wen, Kimberly Maratea, Philip Overend, Steven Fox, Julie Charlton, Simon T Barry, Donald Strickland, MD, Suzanne Jones, PharmD, Howard A. Burris, MD, Carol Greenlees, Alexander MacDonald, J. Elizabeth Pease, PhD, William Donnellan
Journal: Blood
Blood (2017) 130 (Supplement 1): 1368.
https://doi.org/10.1182/blood.V130.Suppl_1.1368.1368
Published: 2017
Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Eunice S. Wang, MD, William Donnellan, Roland B. Walter, MD PhD, Ioannis Mantzaris, MD, Michael B. Maris, MD, Dale L. Bixby, David A. Rizzieri, MD, Stefan Faderl, Madlen Malinowski, Naveen Pemmaraju, MD, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Ross Lindsay, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2583.
https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583
Published: 2017
Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Michael Byrne, MD, William Donnellan, Manish R Patel, MD, Amer M. Zeidan, MD, Mohamad Cherry, MDMS, Maria R. Baer, MD, Amir T. Fathi, MD MD BS, Jason Kaplan, MD, Feng Zhou, Fred Zheng, MD, April M. Barbour, Michael R. Savona, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2585.
https://doi.org/10.1182/blood.V130.Suppl_1.2585.2585
Published: 2017